Literature DB >> 30190304

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging.

Rudolf A Werner1,2, Ralph A Bundschuh3, Lena Bundschuh3, Mehrbod S Javadi1, Jeffrey P Leal1, Takahiro Higuchi2,4, Kenneth J Pienta5, Andreas K Buck2, Martin G Pomper1, Michael A Gorin1,5, Constantin Lapa2, Steven P Rowe6,5.   

Abstract

Recently, the standardized reporting and data system for prostate-specific membrane antigen (PSMA)-targeted PET imaging studies, termed PSMA-RADS version 1.0, was introduced. We aimed to determine the interobserver agreement for applying PSMA-RADS to imaging interpretation of 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) PET examinations in a prospective setting mimicking the typical clinical workflow at a prostate cancer referral center.
Methods: Four readers (2 experienced readers (ERs, >3 y of PSMA-targeted PET interpretation experience) and 2 inexperienced readers (IRs, <1 y of experience)), who had all read the initial publication on PSMA-RADS 1.0, assessed 50 18F-DCFPyL PET/CT studies independently. Per scan, a maximum of 5 target lesions was selected by the observers, and a PSMA-RADS score for every target lesion was recorded. No specific preexisting conditions were placed on the selection of the target lesions, although PSMA-RADS 1.0 suggests that readers focus on the most avid or largest lesions. An overall scan impression based on PSMA-RADS was indicated, and interobserver agreement rates on a target lesion-based, on an organ-based, and on an overall PSMA-RADS score-based level were computed.
Results: The number of target lesions identified by each observer was as follows: ER 1, 123; ER 2, 134; IR 1, 123; and IR 2, 120. Among those selected target lesions, 125 were chosen by at least 2 individual observers (all 4 readers selected the same target lesion in 58 of 125 [46.4%] instances, 3 readers in 40 of 125 [32%], and 2 observers in 27 of 125 [21.6%]). The interobserver agreement for PSMA-RADS scoring among identical target lesions was good (intraclass correlation coefficient [ICC] for 4, 3, and 2 identical target lesions, ≥0.60, respectively). For lymph nodes, an excellent interobserver agreement was derived (ICC, 0.79). The interobserver agreement for an overall scan impression based on PSMA-RADS was also excellent (ICC, 0.84), with a significant difference for ER (ICC, 0.97) vs. IR (ICC, 0.74) (P = 0.005).
Conclusion: PSMA-RADS demonstrated a high concordance rate in this study, even among readers with different levels of experience. This finding suggests that PSMA-RADS can be effectively used for communication with clinicians and can be implemented in the collection of data for large prospective trials.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  18F-DCFPyL; PSMA; PSMA-RADS; interobserver; interreader; prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 30190304      PMCID: PMC6278904          DOI: 10.2967/jnumed.118.217588

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  27 in total

1.  Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists.

Authors:  Andrew B Rosenkrantz; Luke A Ginocchio; Daniel Cornfeld; Adam T Froemming; Rajan T Gupta; Baris Turkbey; Antonio C Westphalen; James S Babb; Daniel J Margolis
Journal:  Radiology       Date:  2016-04-01       Impact factor: 11.105

2.  68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.

Authors:  Jeremie Calais; Johannes Czernin; Minsong Cao; Amar U Kishan; John V Hegde; Narek Shaverdian; Kiri Sandler; Fang-I Chu; Chris R King; Michael L Steinberg; Isabel Rauscher; Nina-Sophie Schmidt-Hegemann; Thorsten Poeppel; Philipp Hetkamp; Francesco Ceci; Ken Herrmann; Wolfgang P Fendler; Matthias Eiber; Nicholas G Nickols
Journal:  J Nucl Med       Date:  2017-11-09       Impact factor: 10.057

3.  Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Authors:  Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal:  J Nucl Med       Date:  2017-09-08       Impact factor: 10.057

4.  PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer.

Authors:  Felix Dietlein; Carsten Kobe; Stephan Neubauer; Matthias Schmidt; Simone Stockter; Thomas Fischer; Klaus Schomäcker; Axel Heidenreich; Boris D Zlatopolskiy; Bernd Neumaier; Alexander Drzezga; Markus Dietlein
Journal:  J Nucl Med       Date:  2016-12-01       Impact factor: 10.057

5.  Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT.

Authors:  Frederik L Giesel; Leon Will; Claudia Kesch; Martin Freitag; Christophe Kremer; Jonas Merkle; Oliver C Neels; Jens Cardinale; Boris Hadaschik; Markus Hohenfellner; Klaus Kopka; Uwe Haberkorn; Clemens Kratochwil
Journal:  J Nucl Med       Date:  2018-02-01       Impact factor: 10.057

Review 6.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

7.  Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.

Authors:  Markus Dietlein; Carsten Kobe; Georg Kuhnert; Simone Stockter; Thomas Fischer; Klaus Schomäcker; Matthias Schmidt; Felix Dietlein; Boris D Zlatopolskiy; Philipp Krapf; Raphael Richarz; Stephan Neubauer; Alexander Drzezga; Bernd Neumaier
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

8.  Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia.

Authors:  Rudolf A Werner; Sara Sheikhbahaei; Krystyna M Jones; Mehrbod S Javadi; Lilja B Solnes; Ashley E Ross; Mohamad E Allaf; Kenneth J Pienta; Constantin Lapa; Andreas K Buck; Takahiro Higuchi; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Ann Nucl Med       Date:  2017-08-22       Impact factor: 2.668

9.  F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.

Authors:  Frederik L Giesel; B Hadaschik; J Cardinale; J Radtke; M Vinsensia; W Lehnert; C Kesch; Y Tolstov; S Singer; N Grabe; S Duensing; M Schäfer; O C Neels; W Mier; U Haberkorn; K Kopka; C Kratochwil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-26       Impact factor: 9.236

10.  Uptake of 18F-DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET Studies.

Authors:  Steven P Rowe; Curtiland Deville; Channing Paller; Steve Y Cho; Elliot K Fishman; Martin G Pomper; Ashley E Ross; Michael A Gorin
Journal:  Tomography       Date:  2015-12
View more
  14 in total

1.  Novel Structured Reporting Systems for Theranostic Radiotracers.

Authors:  Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Stefano Fanti; Mehrbod S Javadi; Takahiro Higuchi; Alexander Weich; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Ken Herrmann; Constantin Lapa; Steven P Rowe
Journal:  J Nucl Med       Date:  2019-02-22       Impact factor: 10.057

2.  High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT.

Authors:  Rudolf A Werner; Thorsten Derlin; Steven P Rowe; Lena Bundschuh; Gabriel T Sheikh; Martin G Pomper; Sebastian Schulz; Takahiro Higuchi; Andreas K Buck; Frank M Bengel; Ralph A Bundschuh; Constantin Lapa
Journal:  J Nucl Med       Date:  2020-08-28       Impact factor: 10.057

3.  Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT.

Authors:  Erin Gomez; Phuoc T Tran; Kenneth J Pienta; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Clin Nucl Med       Date:  2019-04       Impact factor: 7.794

4.  Prospective Evaluation of 18F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI.

Authors:  Sonia Gaur; Esther Mena; Stephanie A Harmon; Maria L Lindenberg; Stephen Adler; Anita T Ton; Joanna H Shih; Sherif Mehralivand; Maria J Merino; Bradford J Wood; Peter A Pinto; Ronnie C Mease; Martin G Pomper; Peter L Choyke; Baris Turkbey
Journal:  AJR Am J Roentgenol       Date:  2020-07-08       Impact factor: 3.959

Review 5.  The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?

Authors:  Rudolf A Werner; Alexander Weich; Malte Kircher; Lilja B Solnes; Mehrbod S Javadi; Takahiro Higuchi; Andreas K Buck; Martin G Pomper; Steven P Rowe; Constantin Lapa
Journal:  Theranostics       Date:  2018-11-29       Impact factor: 11.556

6.  Imaging CAR T cell therapy with PSMA-targeted positron emission tomography.

Authors:  Il Minn; David J Huss; Hye-Hyun Ahn; Tamara M Chinn; Andrew Park; Jon Jones; Mary Brummet; Steven P Rowe; Polina Sysa-Shah; Yong Du; Hyam I Levitsky; Martin G Pomper
Journal:  Sci Adv       Date:  2019-07-03       Impact factor: 14.136

7.  Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer.

Authors:  Wajahat Khatri; Hyun Woo Chung; Rudolf A Werner; Jeffrey P Leal; Kenneth J Pienta; Martin A Lodge; Michael A Gorin; Martin G Pomper; Steven P Rowe
Journal:  Diagnostics (Basel)       Date:  2021-04-07

8.  Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.

Authors:  Steven P Rowe; Xin Li; Bruce J Trock; Rudolf A Werner; Sarah Frey; Michael DiGianvittorio; J Keith Bleiler; Diane K Reyes; Rehab Abdallah; Kenneth J Pienta; Michael A Gorin; Martin G Pomper
Journal:  J Nucl Med       Date:  2019-08-26       Impact factor: 10.057

9.  Exciting Opportunities in Nuclear Medicine Imaging and Therapy.

Authors:  Constantin Lapa
Journal:  J Clin Med       Date:  2019-11-12       Impact factor: 4.241

Review 10.  18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging.

Authors:  Rudolf A Werner; Thorsten Derlin; Constantin Lapa; Sara Sheikbahaei; Takahiro Higuchi; Frederik L Giesel; Spencer Behr; Alexander Drzezga; Hiroyuki Kimura; Andreas K Buck; Frank M Bengel; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.